Does omeprazole increase the risk of Clostridioides difficile infection, and should it be discontinued if a patient develops CDI?

Omeprazole and C. difficile Infection

While omeprazole and other PPIs show an epidemiologic association with increased CDI risk, current evidence does not support routinely discontinuing PPIs solely to prevent or treat CDI, though unnecessary PPIs should always be stopped. 1

Risk Association

The relationship between omeprazole (and PPIs generally) and CDI is well-documented but complex:

• The FDA label explicitly warns that PPI therapy like omeprazole may be associated with increased risk of Clostridioides difficile-associated diarrhea, especially in hospitalized patients, and recommends using the lowest dose and shortest duration appropriate 2

• The 2018 IDSA/SHEA guidelines state clearly: Although there is an epidemiologic association between PPI use and CDI, there is insufficient evidence for discontinuation of PPIs as a measure for preventing CDI 1

• The guidelines emphasize that unnecessary PPIs should always be discontinued, but this is general stewardship rather than a CDI-specific intervention 1

Evidence Quality and Causality Issues

The association faces significant challenges in proving causality:

• Observational studies show associations but extensive confounding makes it difficult to establish true causation 3. Patients on PPIs often have complex comorbidities that independently increase CDI risk

• Meta-analysis data suggests PPI users have 64-84% increased risk of recurrent CDI 4, but these are observational studies with inherent limitations

• Recent mechanistic research (2025) suggests the increased risk is likely due to pH changes in the gastrointestinal tract rather than direct drug-microbiome interactions 5, which provides biological plausibility but doesn't change clinical recommendations

• Some studies show omeprazole specifically may increase risk 2-fold 6 and can affect ST81 strain behavior 7, but these are single-center or mechanistic studies

Clinical Management Algorithm

When a Patient Develops CDI:

1. Discontinue the inciting antibiotic as soon as possible (strong recommendation) 1

2. Evaluate PPI necessity:

   • If the PPI has a clear, ongoing indication (active peptic ulcer, severe GERD with esophagitis, high-dose NSAID use) → Continue the PPI
   • If the PPI was started for vague symptoms, stress ulcer prophylaxis outside ICU, or has no documented indication → Discontinue it as part of general medication stewardship

3. Treat CDI appropriately:

   • Non-severe: Vancomycin 125 mg PO four times daily OR fidaxomicin 200 mg PO twice daily for 10 days 1
   • Severe: Same regimen as non-severe 1
   • Fulminant: Vancomycin 500 mg PO four times daily ± rectal vancomycin + IV metronidazole 1

For CDI Prevention in At-Risk Patients:

• Do not routinely discontinue PPIs solely for CDI prevention 1
• Do discontinue unnecessary PPIs as part of antimicrobial and medication stewardship 1
• Focus prevention efforts on proven interventions: antibiotic stewardship, contact precautions, environmental cleaning 1

Key Caveats

• The association is real but confounded: Patients requiring PPIs often have characteristics (advanced age, comorbidities, healthcare exposure) that independently increase CDI risk

• Recurrent CDI may have stronger association: Some evidence suggests PPI use during hospitalization increases recurrence risk more substantially 4, making PPI reassessment particularly important in patients with prior CDI

• Consider the indication strength: A patient with Barrett's esophagus has a much stronger indication than someone on "empiric" PPI therapy for nonspecific symptoms

• Document your reasoning: If continuing a PPI in a CDI patient, document the specific indication. If discontinuing, note it was unnecessary rather than stopped "for CDI"

The bottom line: Treat CDI aggressively with appropriate antibiotics, stop unnecessary PPIs as good stewardship practice, but don't withhold indicated PPI therapy based on CDI concerns alone.